Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Genomic profiling in luminal breast cancer.

Literature DB >> 24550749

Genomic profiling in luminal breast cancer.

Oleg Gluz¹, Daniel Hofmann¹, Rachel Würstlein², Cornelia Liedtke³, Ulrike Nitz¹, Nadia Harbeck².

Abstract

The developments in gene expression analysis have made it possible to sub-classify hormone receptor-positive (luminal) breast cancer in different prognostic subgroups. This sub-classification is currently used in clinical routine as prognostic signature (e.g. 21-gene Onoctype DX®, 70-gene Mammaprint®). As yet, the optimal method for sub-classification has not been defined. Moreover, there is no evidence from prospective trials. This review explores widely used genomic signatures in luminal breast cancer, making a critical appraisal of evidence from retrospective/prospective trials. It is based on systematic literature search performed using Medline (accessed September 2013) and abstracts presented at the Annual Meeting of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium.

Entities: Disease

Keywords: Biomarker; Breast cancer; Gene expression; Luminal breast cancer; Prognostic markers

Year: 2013 PMID： 24550749 PMCID： PMC3919430 DOI： 10.1159/000357535

Source DB: PubMed Journal: Breast Care (Basel) ISSN： 1661-3791 Impact factor: 2.860

72 in total

1. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors: José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245

2. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Authors: Stella Mook; Marjanka K Schmidt; Giuseppe Viale; Giancarlo Pruneri; Inge Eekhout; Arno Floore; Annuska M Glas; Jan Bogaerts; Fatima Cardoso; Martine J Piccart-Gebhart; Emiel T Rutgers; Laura J Van't Veer
Journal: Breast Cancer Res Treat Date: 2008-07-27 Impact factor: 4.872

3. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Authors: M Gnant; I Sestak; M Filipits; M Dowsett; M Balic; E Lopez-Knowles; R Greil; P Dubsky; H Stoeger; M Rudas; R Jakesz; S Ferree; J W Cowens; T Nielsen; C Schaper; C Fesl; J Cuzick
Journal: Ann Oncol Date: 2015-05-01 Impact factor: 32.976

4. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.

Authors: Aleix Prat; Maggie Chon U Cheang; Miguel Martín; Joel S Parker; Eva Carrasco; Rosalía Caballero; Scott Tyldesley; Karen Gelmon; Philip S Bernard; Torsten O Nielsen; Charles M Perou
Journal: J Clin Oncol Date: 2012-12-10 Impact factor: 44.544

5. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.

Authors: Xiao-Jun Ma; Susan G Hilsenbeck; Wilson Wang; Li Ding; Dennis C Sgroi; Richard A Bender; C Kent Osborne; D Craig Allred; Mark G Erlander
Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544

6. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.

Authors: Frédérique Penault-Llorca; Fabrice André; Christine Sagan; Magali Lacroix-Triki; Yves Denoux; Veronique Verriele; Jocelyne Jacquemier; Marie Christine Baranzelli; Frederic Bibeau; Martine Antoine; Nicole Lagarde; Anne-Laure Martin; Bernard Asselain; Henri Roché
Journal: J Clin Oncol Date: 2009-04-20 Impact factor: 44.544

7. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.

Authors: Yi Zhang; Catherine A Schnabel; Brock E Schroeder; Piiha-Lotta Jerevall; Rachel C Jankowitz; Tommy Fornander; Olle Stål; Adam M Brufsky; Dennis Sgroi; Mark G Erlander
Journal: Clin Cancer Res Date: 2013-06-11 Impact factor: 12.531

8. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.

Authors: Daniel Hofmann; Ulrike Nitz; Oleg Gluz; Ronald E Kates; Timo Schinkoethe; Peter Staib; Nadia Harbeck
Journal: Trials Date: 2013-08-19 Impact factor: 2.279

9. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Authors: Mitch Dowsett; Ivana Sestak; Elena Lopez-Knowles; Kalvinder Sidhu; Anita K Dunbier; J Wayne Cowens; Sean Ferree; James Storhoff; Carl Schaper; Jack Cuzick
Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544

10. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.

Authors: Miguel Martín; Aleix Prat; Alvaro Rodríguez-Lescure; Rosalía Caballero; Mark T W Ebbert; Blanca Munárriz; Manuel Ruiz-Borrego; Roy R L Bastien; Carmen Crespo; Carole Davis; César A Rodríguez; José M López-Vega; Vicente Furió; Ana M García; Maribel Casas; Matthew J Ellis; Donald A Berry; Brandelyn N Pitcher; Lyndsay Harris; Amparo Ruiz; Eric Winer; Clifford Hudis; Inge J Stijleman; David P Tuck; Eva Carrasco; Charles M Perou; Philip S Bernard
Journal: Breast Cancer Res Treat Date: 2013-02-20 Impact factor: 4.872

7 in total

Genomic profiling in luminal breast cancer.

1. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

2. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

3. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

4. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.

5. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.

6. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.

7. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.

8. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.

9. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

10. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.

Review 1. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion.

2. Bridging the gap - an update of translational research in breast cancer.

Review 3. Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics.

4. "Upstream Analysis": An Integrated Promoter-Pathway Analysis Approach to Causal Interpretation of Microarray Data.

Review 5. Genomic Assays in Node Positive Breast Cancer Patients: A Review.

Review 6. Genomic Signatures in Luminal Breast Cancer.

7. Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.